Galactagogue Use in Lactating Women With Low Milk Supply

Sponsor
Winthrop University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05398367
Collaborator
(none)
120
1
4
24
5

Study Details

Study Description

Brief Summary

This study aims to determine whether a 20-day supplement with either Oat Mama Lactation Supplement, moringa, or shatavari has any impact on milk production through an increase in serum prolactin levels when compared to the placebo group. This data will be used to determine if clinical recommendations can be made for the use of the studied supplements in increasing milk supply.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Galactagogue Supplement for Treatment of Low Milk Supply
N/A

Detailed Description

This study will be a double-blind randomized control trial where eligible participants will be randomized into one of four treatment groups: Oat Mama Lactation Supplement (O), moringa supplement (M), shatavari supplement (S), or control (C). All participants will receive a supplement or placebo for consumption throughout the 20-day trial period, and all participants will receive support from a lactation consultant once per week to receive appropriate guidance for increasing milk supply. 24-hour milk output will be recorded on day 1, 10, and 20 using either pre- and post-feeding weights, 24-hour pump output, or a combination of both. Additionally, blood samples will be taken on day 1, 10, and 20 and serum will be isolated for later analysis of serum prolactin levels.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Participants will be randomized into one of four treatment groups: Oat Mama Lactation Supplement (O), moringa supplement (M), shatavari supplement (S), or control (C).Participants will be randomized into one of four treatment groups: Oat Mama Lactation Supplement (O), moringa supplement (M), shatavari supplement (S), or control (C).
Masking:
Triple (Participant, Care Provider, Investigator)
Masking Description:
Double-blind randomized controlled trial
Primary Purpose:
Treatment
Official Title:
Effect of Single Ingredient and Blend Galactagogue Supplements on Increasing Milk Supply in Lactating Women Experiencing Diagnosed or Perceived Low Milk Supply
Anticipated Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Mar 1, 2023
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Oat Mama Lactation Supplement

Participants will receive a 20 day supply of oat mama lactation supplement for consumption per the manufacturer instructions

Dietary Supplement: Galactagogue Supplement for Treatment of Low Milk Supply
Participants will consume a commercially available dietary supplement on the market for augmentation of breast milk production in lactating women with low milk supply

Experimental: Moringa Supplement

Participants will receive a 20 day supply of moringa supplement for consumption per the manufacturer instructions

Dietary Supplement: Galactagogue Supplement for Treatment of Low Milk Supply
Participants will consume a commercially available dietary supplement on the market for augmentation of breast milk production in lactating women with low milk supply

Experimental: Shatavari Supplement

Participants will receive a 20 day supply of shatavari supplement for consumption per the manufacturer instructions

Dietary Supplement: Galactagogue Supplement for Treatment of Low Milk Supply
Participants will consume a commercially available dietary supplement on the market for augmentation of breast milk production in lactating women with low milk supply

Placebo Comparator: Placebo

Participants will receive a 20 day supply of placebo pills containing a mixture of flour and brown sugar. Participants will consume 2 placebo pills once per day for 20 days.

Dietary Supplement: Galactagogue Supplement for Treatment of Low Milk Supply
Participants will consume a commercially available dietary supplement on the market for augmentation of breast milk production in lactating women with low milk supply

Outcome Measures

Primary Outcome Measures

  1. Change in Breast Milk Supply [Intervention will last 20 days and 24-hour breast milk expression volume will be measured on day 1, 10, and 20 and used to calculate change in 24-hour breast milk expression volume over the trial period]

    Change in breast milk supply will be evaluated using 24-hour breast milk expression volume

  2. Change in Serum Prolactin [Intervention will last 20 days and blood samples will be taken on day 1, 10, am 20 and change in serum prolactin will be measured using a human serum prolactin ELISA kit]

    Change in serum prolactin levels will be evaluated by taking blood samples on day 1, 10, and 20 and measuring serum prolactin using a human serum prolactin ELISA kit

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria: Participants in the study must:
  • Be struggling with diagnosed or perceived low milk supply

  • Be willing to consume a randomly assigned galactagogue or placebo supplement

  • Be willing to provide a blood sample at each lactation consult (day 1, 10, 20)

  • Be willing to provide 24-hour expressed milk volume either using pre- and post-feed weights, total pump output, or a combination of both on day 1, 10, and 20

Exclusion Criteria: Participants will be excluded if:
  • They have a history of breast reduction

  • They have a history of utilizing in vitro fertilization

  • They are not a biological female with mammary glands present for producing milk

  • They have consumed galactagogues with the intention of increasing their milk supply during the current lactation cycle

  • They are under age 18 or above age 39

Contacts and Locations

Locations

Site City State Country Postal Code
1 Winthrop University Rock Hill South Carolina United States 29733

Sponsors and Collaborators

  • Winthrop University

Investigators

  • Principal Investigator: Hope K Lima, PhD, Winthrop University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hope Lima, Assistant Professor and Graduate Director, Winthrop University
ClinicalTrials.gov Identifier:
NCT05398367
Other Study ID Numbers:
  • IRB22107R
First Posted:
Jun 1, 2022
Last Update Posted:
Jun 1, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 1, 2022